Related references
Note: Only part of the references are listed.Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
Joaquim J. Ferreira et al.
NEUROLOGY AND THERAPY (2022)
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
Jose-Francisco Rocha et al.
FRONTIERS IN NEUROLOGY (2021)
Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities
C. Warren Olanow et al.
MOVEMENT DISORDERS (2020)
Safety Profile of Opicapone in the Management of Parkinson's Disease
Andrew Lees et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine
Margherita Fabbri et al.
MOVEMENT DISORDERS (2018)
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial
Andrew J. Lees et al.
JAMA NEUROLOGY (2017)
Opicapone: A Review in Parkinson's Disease
Lesley J. Scott
DRUGS (2016)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
Joaquim J. Ferreira et al.
LANCET NEUROLOGY (2016)
Levodopa therapy for Parkinson disease A look backward and forward
Peter A. LeWitt et al.
NEUROLOGY (2016)
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Roberto Cilia et al.
BRAIN (2014)
Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
Luis Almeida et al.
CLINICAL PHARMACOKINETICS (2013)
Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments
David Salat et al.
JOURNAL OF PARKINSONS DISEASE (2013)
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
Nicola Tambasco et al.
PARKINSONS DISEASE (2012)
When Do Levodopa Motor Fluctuations First Appear in Parkinson's Disease?
Fabrizio Stocchi et al.
EUROPEAN NEUROLOGY (2010)
Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase
Laszlo E. Kiss et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Adherence to Antiparkinson Medication in a Multicenter European Study
Donald Grosset et al.
MOVEMENT DISORDERS (2009)
Priming for L-dopa-induced dyskinesia in Parkinson's disease: A feature inherent to the treatment or the disease?
Agnes Nadjar et al.
PROGRESS IN NEUROBIOLOGY (2009)
Parkinson's disease: Levodopa-induced dyskinesia and signal transduction
Emanuela Santini et al.
FEBS JOURNAL (2008)
Tolcapone: An efficacy and safety review (2007)
C. Warren Olanow et al.
CLINICAL NEUROPHARMACOLOGY (2007)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Share Paper
